Health Condition 1: null- Parkinson Disease Health Condition 2: G20- Parkinsons disease
Conditions
Interventions
Intervention1: Preladenant (SCH 420814): 2, 5, or 10 mg Preladenant tablets, given orally twice daily for 40 weeks
Control Intervention1: Rasagiline: 1 mg Rasagiline tablet given orally once a day for
Sponsors
Merck Sharp Dohme
Fulford India Limited
Eligibility
Inclusion criteria
Inclusion criteria: - Participants who have completed the 12-week treatment period of the parent trial, P04938 or P07037. - Participants must be willing and able to provide written informed consent for P06153. - Participants must be able to adhere to dose and visit schedules. - Participants must be taking levo-dopa (L-dopa). - Participants may be taking additional adjunct PD medications (e.g., dopamine agonists, entacapone). - Each participant must have results of clinical laboratory tests (hematology, blood chemistries, and urinalysis) within normal limits or clinically acceptable to the investigator as evidenced by the last available test results from the parent study (P04938 or P07037), and no results fall within the parameters for exclusion described below in the exclusion criterion for liver-related findings. - There has been no change in, or there has been no finding to warrant checking, serology status (for cytomegalovirus [CMV], Epstein-Barr virus [EBV], and Hepatitis B, C, and E). - Each participant must have results of a physical examination within normal limits, including blood pressure, within normal limits or clinically acceptable limits to the investigator, and not within the parameters for exclusion described below in the exclusion criterion for blood pressure. - All participants who are sexually active or plan to be sexually active agree to use a highly effective method of birth control while the participant is in the study and for 2 weeks after the last dose of study drug. A male participant must not donate sperm within 2 weeks after the last dose of study drug.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: - Any participant who discontinued from P04938 or P07037 for any reason. - Any participant with a severe or ongoing unstable medical condition (e.g. any form of clinically significant cardiac disease symptomatic orthostatic hypotension seizures or alcohol/drug dependence). - Any participant with a history of poorly controlled diabetes (e.g. HbA1c greater than 8.5) or significantly abnormal renal function (e.g. creatinine greater than 2.0 mg/dL) in the opinion of the investigator. - As a continuation of the liver-related withdrawal criteria from the parent studies (P04938 and P07037) any participant with elevated values for alanine aminotransferase (ALT) aspartate aminotransferase (AST) or total bilirubin (T BIL) as evidenced by the most recent chemistry panel results in the parent study meeting any one of the following criteria: - ALT or AST greater than 8 x upper limit of normal (ULN). - ALT or AST greater than 5 x ULN for more than 2 weeks. - ALT or AST greater than 3 x ULN and (T-BIL greater than 2 x ULN or international normalized ratio [INR] greater than 1.5 that is not due to anti-coagulation) at the same visit. - ALT or AST greater than 3 x ULN with the appearance of worsening fatigue nausea vomiting right upper quadrant pain or tenderness fever rash and/or eosinophilia (greater than 5%). - As a continuation of the blood pressure (BP) withdrawal criteria from the parent study (P04938 or P07037) any participant meeting the following criteria for the second of two consecutive visits separated by 7 days (i.e. the participant met one of the BP criteria once already 7 days before the P06153 screening visit): - Systolic BP greater than or equal to 180 mm Hg or diastolic BP greater than or equal to 105 mm Hg or - An elevation from baseline BP in the parent study (P04938 or P07037) of systolic BP greater than or equal to 40 mm Hg or diastolic BP greater than or equal to 20 mm Hg. - A participant must not have a history within the past 5 years of a primary or recurrent malignant disease with the exception of adequately treated basal cell or squamous cell skin cancer in situ cervical cancer or in situ prostate cancer with a normal prostate-specific antigen (PSA) post resection. - Any participant with an average daily consumption of more than three 4-ounce glasses (118 mL) of wine or the equivalent. - A participant must not have received certain prespecified medications or ingested high tyramine-containing aged cheeses (e.g. Stilton) for a prespecified time window before the trial during the trial and for 2 weeks after the trial. - Any participant with allergy/sensitivity to the investigational products or their excipients. - Any female participant breast feeding or considering breast feeding. - Any female participant pregnant or intending to become pregnant. - Any participant with any clinically significant condition or situation other than the condition being studied that in the opinion of the investigator would interfere with the trial evaluations or optimal participation in the trial. - Any participant with a member or a family member of the personnel of the investigational or sponsor staff directly involved with this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Incidence of systolic blood pressure (SBP) â?¥ 180 mm Hg 2. Incidence of diastolic blood pressure (DBP) â?¥ 105 mm Hg 3. Incidence of alanine aminotransferase (ALT) â?¥ 3 x upper limit of normal and with a â?¥10% increase from baseline 4. Incidence of aspartate aminotransferase (AST) â?¥ 3 x upper limit of normal and with a â?¥10% increase from baseline 5. Columbia Suicide Severity Rating Scale (CSSRS): Suicidality, Suicidal Behavior, Suicidal Ideation 6. Epworth Sleepiness Scale ScoreTimepoint: 1.Up to 42 weeks from the beginning of P06153 2.Up to 42 weeks from the beginning of P06153 3.Up to 42 weeks from the beginning of P06153 4.Up to 42 weeks from the beginning of P06153 5.Up to 40 weeks from the beginning of P06153 6.Screening and 40 weeks from the beginning of P06153 | — |
Secondary
| Measure | Time frame |
|---|---|
| To characterize the long-term efficacy of preladenant in subjects with moderate to severe PD.Timepoint: Up to 42 weeks from the beginning of P06153 | — |
Countries
Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Finland, France, Germany, India, Ireland, Israel, Italy, Latvia, Lithuania, Mexico, Netherlands, New Zealand, Peru, Poland, Portugal, Russian Federation, Serbia, South Africa, Spain, Sweden, Turkey, Ukraine, United Kingdom, United States of America
Contacts
Public ContactDr Monisha Sharma
MSD Pharmaceuticals Pvt Ltd.
Outcome results
None listed